Add to MyPages

This page will be saved to Cincinnati Children's MyPages, a collection of your favorite places. You can view, organize, or delete your favorites at any time.

Page Title:

Description: (optional)

E-mail this page

(All fields required)

Recipient's e-mail address

Please enter a valid e-mail.

Your name

Please enter your name.

Your e-mail

Please enter a valid e-mail.

Share this on:

Sign into CCHMC

User Name

Password

New?

Forgot Password

Biographies

Find another Doctor or Researcher

High Res

Jennifer M. Kaplan, MD, MS

Assistant Professor, UC Department of Pediatrics

Phone: 513-636-4259

Email: jennifer.kaplan@cchmc.org

Show All

Specialties

Intensive care; respiratory failure; multi-organ failure; sepsis; trauma; inflammation; obesity; PPARg

Biography

My long term career goal is to improve the outcomes of critically ill children. I began my research career in fellowship studying sepsis, driven by the realization that there are few clinical therapies that improve outcomes in critically ill children with severe infections. I focused on the nuclear receptor PPARg as a potential target to alter the sepsis-induced inflammatory state. PPARg is a nuclear receptor with effects on lipid and glucose metabolism, atherosclerosis and inflammation. I elected to extend my fellowship a fourth year to complete training in molecular epidemiology and the Masters of Science program at the University of Cincinnati Academic Health Center. I received grant funding from the Translational Research Initiative and the NIH K12 Child Health Research Career Development Award at CCHMC to investigate the alteration of PPARg in peripheral blood cells from children with sepsis. I am a recipient of an NIH Mentored Clinical Scientist Research Career Development Award (K08).

Education and Training

MS: Epidemiology, University of Cincinnati College of Medicine, Cincinnati, OH.

MD: University of Cincinnati, Cincinnati, OH, 1999.

BA: Washington University in St. Louis, St. Louis, Missouri.

Fellowship: Pediatric Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Residency: Pediatrics, Orlando Regional Healthcare, Orlando, FL.

Certification: Pediatric Critical Care Medicine, Pediatrics.

Publications

View PubMed Publications.

Wong HR, Cvijanovich N, Allen G, Thomas N, Freishtat R, Anas N, Meyer K, Checchia P, Lin R, Shanley T, Bigham M, Wheeler DS, Doughty LA Tegtmeyer K, Poynter SE, Kaplan JM, Chima RS, Stalets E, Basu RK, Varisco B, Barr F. Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med. 2011 Jun 23. Epub ahead of print.

Kaplan JM, Zingarelli B. Novel therapeutic agents in pediatric sepsis: peroxisome proliferator receptor g (PPARg). The Open Inflammation Journal. 2011; 4: 117-121.

Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011; 12: 165-173.

Sherwin CMT, Ding L, Kaplan J, Spigarelli MG, Vinks AA. Optimal design for a single dose, sparse sampling, pharmacokinetic study in pediatrics subpopulations: A proposed study of pioglitazone in septic pediatric patients. Journal of Pharmacokinetics and Pharmacodynamics. 2011; 38:433-447.

Kaplan JM, Hake P, Denenberg A, Nowell M, Piraino G, Zingarelli B. Phosphorylation of Extracellular Signal-Regulated Kinase (ERK)-1/2 is Associated with the Downregulation of Peroxisome Proliferator Activated Receptor (PPAR)-g During Polymicrobial Sepsis. Mol Med. 2010 Nov-Dec; 16(11-12): 491-7.

Kaplan JM, Denenberg A, Monaco M, Nowell M, Wong H, Zingarelli B. Changes in Peroxisome Proliferator Activated Receptor-gamma Activity in Children with Septic Shock. Intensive Care Med. 2010 Jan; 36(1): 123-130.

Kaplan JM, O’Connor M, Zingarelli B. Peroxisome Proliferator Activated Receptor-g is Required for the Inhibitory Effect of Ciglitazone but not 15-Deoxy-Δ^12,14-Prostaglandin J₂ on the NF-kB Pathway in Human Endothelial Cells. Shock. 2007 Dec; 28(6): 722-726.

Kaplan JM, Ancheta R, Jacobs BR. Inpatient Verbal Orders and the Impact of Computerized Provider Order Entry. J Pediatr. 2006 Oct; 149(4): 461-467.

Kaplan JM, Cook JA, Hake PW, O’Connor M, Burroughs TJ, Zingarelli B. 15-Deoxy-Δ^12,14-Prostaglandin J₂ (15d-PGJ₂), A Peroxisome Proliferator Activated Receptor-g Ligand, Reduces Tissue Leukosequestration and Mortality in Endotoxic Shock. Shock. 2005 July; 24(1): 59-65.

Kaplan J, O’Connor M, Hake PW, Zingarelli B. Inhibitors of Poly (ADP-Ribose) Polymerase Ameliorate Myocardial Reperfusion Injury by Modulation of Activator Protein-1 and Neutrophil Infiltration. Shock. 2005 Mar; 23(3):233-238.